CN108024986A - 预防铂药物的毒性的方法 - Google Patents

预防铂药物的毒性的方法 Download PDF

Info

Publication number
CN108024986A
CN108024986A CN201680053118.8A CN201680053118A CN108024986A CN 108024986 A CN108024986 A CN 108024986A CN 201680053118 A CN201680053118 A CN 201680053118A CN 108024986 A CN108024986 A CN 108024986A
Authority
CN
China
Prior art keywords
oct2
subject
cancer
inhibitor
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680053118.8A
Other languages
English (en)
Chinese (zh)
Inventor
Y·黄
D·P·布里东
X·张
C·M·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maim Biopharmaceutical Ltd By Share Ltd
Original Assignee
Maim Biopharmaceutical Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maim Biopharmaceutical Ltd By Share Ltd filed Critical Maim Biopharmaceutical Ltd By Share Ltd
Publication of CN108024986A publication Critical patent/CN108024986A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680053118.8A 2015-07-16 2016-07-15 预防铂药物的毒性的方法 Pending CN108024986A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193529P 2015-07-16 2015-07-16
US62/193,529 2015-07-16
PCT/US2016/042673 WO2017011816A1 (en) 2015-07-16 2016-07-15 Methods of preventing toxicity of platinum drugs

Publications (1)

Publication Number Publication Date
CN108024986A true CN108024986A (zh) 2018-05-11

Family

ID=57757682

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680053118.8A Pending CN108024986A (zh) 2015-07-16 2016-07-15 预防铂药物的毒性的方法

Country Status (6)

Country Link
US (2) US11197862B2 (https=)
EP (2) EP3777851B1 (https=)
JP (2) JP6851639B2 (https=)
CN (1) CN108024986A (https=)
CA (1) CA2990686A1 (https=)
WO (1) WO2017011816A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109596818A (zh) * 2018-12-13 2019-04-09 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
CN111110675A (zh) * 2020-02-25 2020-05-08 浙江大学 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用
CN113527333A (zh) * 2020-04-13 2021-10-22 南开大学 具有生物活性的度鲁特韦衍生物及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990686A1 (en) * 2015-07-16 2017-01-19 Amari Biopharma, Inc. Methods of preventing toxicity of platinum drugs comprising administering an oct monitor
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
WO2021034627A1 (en) * 2019-08-16 2021-02-25 Purdue Research Foundation Small molecule stimulators of the core particle of the proteasome
CN111067894A (zh) * 2020-01-14 2020-04-28 广东药科大学 咪康唑在制备抗肺鳞癌药物和顺铂增敏剂中的应用
WO2022244757A1 (ja) 2021-05-18 2022-11-24 株式会社Ｌｔｔバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090311A1 (en) * 2008-02-18 2009-08-19 Laboratorios Del. Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032172A2 (en) * 2007-08-31 2009-03-12 Massachusetts Institute Of Technology Platinum compositions as treatment for oct-related cancers
ES2665042T3 (es) 2008-02-18 2018-04-24 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos que se unen a ligandos del receptor sigma para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
EP2854829A1 (en) * 2012-05-30 2015-04-08 Sensorion Methods for treating vestibulotoxicity
CA2891855A1 (en) 2012-12-21 2014-06-26 Sykehuset Sorlandet Hf Egfr targeted therapy of neurological disorders and pain
CA2990686A1 (en) * 2015-07-16 2017-01-19 Amari Biopharma, Inc. Methods of preventing toxicity of platinum drugs comprising administering an oct monitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090311A1 (en) * 2008-02-18 2009-08-19 Laboratorios Del. Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JA SPRO等: "Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance", 《CLINICAL PHARMACOLOGY THERAPEUTICS》 *
JASON A. SPROWL等: "Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2", 《PNAS》 *
MACKENZIE L. COTTRELL 等: "Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir"", 《CLIN PHARMACOKINET》 *
R. BARCELO等: "Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: Description of four cases", 《ANNALS OF ONCOLOGY》 *
SALIHA HARRACH等: "Role of transporters in the distribution of platinum based drugs", 《FRONT. PHARMACOL.》 *
YASUTO KIDO等: "Profiling of a Prescription Drug Library for Potential Renal Drug_Drug Interactions Mediated by the Organic Cation Transporter 2", 《J. MED. CHEM.》 *
林小田: "《现代肝病诊断与治疗》", 31 January 2013, 军事医学科学出版社 *
贾玉峰等: "《现代临床肿瘤诊疗最新进展》", 31 March 2015, 西安交通大学出版社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109596818A (zh) * 2018-12-13 2019-04-09 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
CN111110675A (zh) * 2020-02-25 2020-05-08 浙江大学 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用
WO2021169194A1 (zh) * 2020-02-25 2021-09-02 浙江大学 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用
CN113527333A (zh) * 2020-04-13 2021-10-22 南开大学 具有生物活性的度鲁特韦衍生物及其制备方法和应用

Also Published As

Publication number Publication date
US11197862B2 (en) 2021-12-14
JP2021080296A (ja) 2021-05-27
JP7117797B2 (ja) 2022-08-15
EP3777851B1 (en) 2022-12-28
WO2017011816A1 (en) 2017-01-19
US20220202823A1 (en) 2022-06-30
US20180207169A1 (en) 2018-07-26
CA2990686A1 (en) 2017-01-19
JP2018521133A (ja) 2018-08-02
JP6851639B2 (ja) 2021-03-31
EP3322414A1 (en) 2018-05-23
EP3322414B1 (en) 2020-09-30
EP3322414A4 (en) 2019-02-06
EP3777851A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
JP7117797B2 (ja) プラチナ薬剤の毒性の予防方法
US11084828B2 (en) Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease
US9546176B2 (en) Small molecule bicyclic and tricyclic CFTR correctors
Lou et al. Ginkgetin induces autophagic cell death through p62/SQSTM1-mediated autolysosome formation and redox setting in non-small cell lung cancer
US8628752B2 (en) Methods of identifying HSP90 inhibitors with less ocular toxicity
AU2010223058A1 (en) Kinase protein binding inhibitors
US20200345734A1 (en) Methods of treating ocular conditions
US20220062291A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity
Menon et al. Ligand modulation of a dinuclear platinum compound leads to mechanistic differences in cell cycle progression and arrest
US20170326114A1 (en) Cognitive function
CN105682660A (zh) 通过与亲脂性他汀类药物的组合使用加强甲氨蝶呤的作用
Capelôa et al. Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate
HK40047406A (en) Selective oct2 inhibitors for use in preventing toxicity of platinum drugs
HK1254122A1 (en) Methods of preventing toxicity of platinum drugs
US9675608B2 (en) Identification of natural small-molecules AMPK activators for treatment of cancers or multidrug-resistant cancers
CN113874029B (zh) 基于cp2c靶向肽的抗癌剂
US20240342168A1 (en) Small molecule inhibitors for anti-cancer combination therapy
US20200330437A1 (en) Pharmaceutical composition for treating or preventing parkinson's disease comprising stt as an active ingredient
US12616750B2 (en) Combination therapy utilizing DNA alkylating agents and ATR inhibitors
US10973840B2 (en) Methods of sensitizing tumor cells to weak base chemotherapeutic drugs
CN105592845A (zh) 拉帕酚f抑制肿瘤细胞生长的用途
Chan Elucidation of the molecular targets and cellular actions of tetrandrine–a novel autophagic inducing compound
Simon Physico-chemical characterization of beta-amyloid oligomers and study of their function in biological processes at molecular level

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254122

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Zongwei biomedical Co.,Ltd.

Address before: California, USA

Applicant before: AMARI BIOPARMA, Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180511

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1254122

Country of ref document: HK